NVO Jan 2026 145.000 call
| Previous close | 21.95 |
| Open | 21.80 |
| Bid | 21.55 |
| Ask | 22.75 |
| Strike | 145.00 |
| Expiry date | 2026-01-16 |
| Day's range | 21.75 - 21.80 |
| Contract range | N/A |
| Volume | |
| Open interest | 205 |
GlobeNewswireNovo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 27 May 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the programme initiate
Insider MonkeyThe Biggest Biotechnology Company in Europe
We’ve recently covered a list of 20 Biggest Publicly-Traded Biotech Companies based on market caps that you can visit here. Biotechnology and Industry 2023: Market Growth, Transformations, and Technological Milestones The global biotechnology market was valued at approximately $1.55 trillion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 13.96% from 2024 to 2030, reaching a staggering $3.88 trillion by 2030. The […]
BloombergNovo’s Ozempic Slashes Risk of Death in Kidney Disease Study
(Bloomberg) -- Novo Nordisk A/S’s blockbuster diabetes drug Ozempic cut patients’ risk of dying in a kidney-disease study, the latest research pointing to the medicine’s usefulness in a constellation of disorders. Most Read from BloombergWhat the Trump Jury Saw as Evidence Against Him in 12 ImagesSingapore Air Changes Seatbelt Rules After Fatal TurbulenceSpaceX Weighs Plan to Sell Shares at $200 Billion ValuationThe Rise and Fall of Simon Sadler's Segantii, One of Asia's Most Successful Hedge Fu
